The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Research > Alizyme Therapeutics Ltd.

Alizyme Therapeutics Ltd.
 PROFILE
Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them; it targets conditions that are seen primarily in industrialized countries, including obesity, irritable bowel syndrome, inflammatory bowel disease, and Type II diabetes (often associated with obesity). Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.

 COMPETITION
Ergo Science Corporation (ERGO)
GlaxoSmithKline plc (GSK)
Roche Group (ROHHY)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 0.00

 KEY PEOPLE
• Richard M. J. Palmer
    CEO
• Timothy P. McCarthy
    CFO

 CONTACT INFO
Granta Park, Great Abington,
Cambridge CB1 665, United Kingdom
Phone: 44-1223-896-000
Fax: 44-1223-896-001
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001